Despite significant advances in our understanding of the molecular pathology of bladder cancer, it remains a significant health problem with high morbidity and mortality associated with muscle-invasive bladder cancer (stages T2+), and high costs associated with the surveillance of non-muscle-invasive bladder cancer (NMIBC, stages Ta/T1/Tis). Moreover, current diagnostic biomarkers are suboptimal and of poor utility for low grade disease and surveillance. In this study we show that the Engrailed-2 (EN2) transcription factor is expressed in, and secreted by, bladder cancer cell lines and patient tumor specimens, justifying an evaluation of urinary EN2 as a diagnostic biomarker in bladder cancer using archived samples from an established biospecimen collection. In patients with NMIBC, urinary EN2 was detected in most cases with an overall sensitivity of 82% and specificity of 75%. The sensitivity for stage Ta and T1 tumors was 71% and 76%, respectively, and 94% for stage T2+ tumors. This compares favorably with existing markers.
Introduction
Urothelial carcinoma of the urinary bladder (UCB) is the fourth and ninth most common cancer amongst men and women, respectively, in Europe and North America, with an estimated prevalence of 500,000 1 . Long term surveillance is required in the majority of cases, involving regular cystoscopy. UCB results in significant mortality, with overall 5-year survival rates of 57% and 47% for men and women respectively when the disease presents as muscle-invasive 1 .
As a result, UCB also represents a significant economic burden to healthcare systems as the most expensive malignancy to manage on a per patient basis from diagnosis to death 2, 3 Around 75-80% of patients present with nonmuscle-invasive disease (NMIBC), but recurrence and progression are significant issues, compelling current guidelines to recommend long-term surveillance 4 . There is therefore an urgent and unmet need to identify and validate accurate urinary biomarkers for the detection of disease recurrence in order to improve quality of life for NMIBC patients and reduce costs for healthcare providers, whilst maintaining or improving current outcomes.
Characteristics of effective biomarkers include cancer-specific expression and release from tumors. One gene that has recently been shown to have these properties is the transcription factor Engrailed-2 (EN2), which is expressed in both breast cancer 5 and prostate cancer 6 . The former study showed that EN2 has oncogenic potential, as its forced expression in a non-malignant mammary epithelial line increased cell proliferation, survival and invasion 5 .
We have recently shown that EN2 is also expressed in human prostate 4 cancer cell lines and patient tumors. Furthermore, full length EN2 protein can be released from prostatic cancer acini and ducts, and detected in the urine of prostate cancer patients, thus representing a potential diagnostic biomarker 6, 7 . In this study we show that EN2 is also expressed by bladder cancer tumors and is potentially a specific and sensitive biomarker for bladder cancer, even when the disease presents at early, non-invasive stages. Growth conditions for the cell lines were as previously described 6, 8 . The conditioned media used for EN2 detection was taken from cells grown to 90%
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confluence and then put in serum-free medium for 2 hours.
Paraffin-Embedded Tissues and Immunohistochemistry
Expression of EN2 in UCB and normal bladder tissue was investigated using 3µm thick formalin fixed, paraffin embedded tissue array sections (BL2081, US Biomax, Rockville, MD, USA). Immunohistochemical analysis was performed using a polyclonal rabbit anti-EN2 antibody (Abcam, Cambridge, Cambridgeshire, UK #28731) diluted 1:100 and the ABC detection method with peroxidase block (DakoCytomation). Antigen retrieval was performed using pH9.0 Tris/EDTA buffer (DakoCytomation) and heating in a microwave for 23 minutes.
Immunostaining was assessed by a uropathologist and scored (independently by a second observer) on a 0-3 scale, with 0 representing no apparent staining and 3 very strong staining. The levels of expression in the tissue array cores were scored as no staining (score = 0), tumor with low level staining, cytoplasmic only (score = 1), tumor with moderate staining, cytoplasmic only (score = 2), and tumor with high staining both cytoplasmic and nuclear (score = 3).
Gene expression profiling
Total RNA for gene expression analysis was extracted using TRIZOL (Invitrogen, Paisley, UK), DNase-treated and cleaned up using a Qiagen RNeasy Mini Kit. Whole-genome expression profiling was performed using GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA). 5 µg of total RNA from each cell line was labelled using the WTOvation Pico Target Prep v1.0 system (NuGen Technologies Inc., San Carlos, CA, USA) and hybridised according to the array manufacturer's instructions.
The arrays were scanned and CEL files were imported into Partek Genomics Suite 6.5. Data were normalised and probe intensity measures were generated using the Robust Microarray Analysis (RMA)
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. EN2 mRNA expression levels were represented as log 10 (cell line intensity/NHU-Pool intensity).
cDNA Synthesis and RT-PCR
RNA was extracted from the bladder cancer derived cell lines using the Qiagen RNeasy kit (Qiagen, USA). Three paired biopsy samples of human UCB and normal adjacent bladder were evaluated (one from each of three patients). Ethical approval for the evaluation of these samples was in place (10/H1101/7). All were confirmed histologically as bladder cancer or normal by a specialist uropathologist. cDNA synthesis and RT-PCR were performed as previously described 6 .
EN2 protein detection
EN2 detection by western blotting 6 was carried out as previously described.
For the ELISA, a monoclonal mouse anti-EN2 antibody, APS1, was generated (Antibody Production Services Ltd, Haywards Heath, Sussex, UK) using the synthetically produced EN2 C-terminal 100 amino acids (Biosynthesis Inc, Lewisville, Texas, USA). An APS1-Alkaline phosphatase conjugate was used to detect EN2 captured onto a 96-well plate (Nunc 436014, Rochester, New York, USA). 100 µl of the urine supernatant samples or a dilution of the EN2 fragment in buffer was tested in duplicate. A standard curve was generated from dilution series to allow the concentration of EN2 in each sample to be measured. 
Patients and Controls
Statistical analysis
The GraphPad prism package was used in statistical calculations. To test the significance of differences between mean EN2 concentrations in different patient groups we used an unpaired t-test with Welch's correction. Receiver operator characteristics (ROC) curves were generated for the EN2 and the area under the curve tested for significance using an unpaired t-test against the hypothesis that the real area under the curve was 0·5 (i.e. no diagnostic value). For the qRT-PCR data we used the mean of 3 independent experiments and tested for significance using Student's t-test with Welch's correction.
Results
EN2 expression in UCB
The previous findings that EN2 is expressed by prostate 6 and breast 5 cancer cells led us to determine whether EN2 was also expressed in UCB. Evaluation of gene expression microarray data from a panel of UCB cell lines, including several derived from low grade and low stage UCB revealed that a majority of cell lines express higher levels of EN2 mRNA compared with normal urothelium controls (Fig 1a) . Fig 2a) , squamous cell carcinoma (SCC) (Fig. 2b) and adenocarcinoma of the bladder (Fig 2c) . In TCC tumors, the pattern of EN2 expression was cytoplasmic and nuclear, similar to that observed in prostatic adenocarcinoma. In adenocarcinoma and SCC expression was also cytoplasmic and nuclear but levels more heterogeneous within the same tumor deposit with areas of focal positivity. Scoring the tumor core immunostaining (Fig 2d-g ) revealed no staining for normal bladder tissue but 22-fold higher staining for all tumor types combined and 24-fold higher staining in TCC. SCC and adenocarcinoma had 17-fold and 6.4-fold higher staining than normal bladder, respectively (Fig 3) . Higher grade tumors had progressively less EN2 expression than lower grade tumors -Grade 1 and Grade 2 tumors showed 2.3-fold and 1.9-fold more staining, respectively, than Grade 3 tumors (Fig 3) . No differences in staining were apparent between tumors taken from male and female patients, nor was there any apparent relationship between staining and patient age (data not shown).
EN2 protein is present in the urine of bladder cancer patients
Given the expression of EN2 in UCB cell lines and tissue sections, secretion of EN2 by cell lines and our previous findings in prostate cancer, we assessed urinary EN2 levels in an independent cohort of patients with and without UCB (BCPP 10 ). The characteristics of the patients included in the study are shown 11 in Table 1 . For those patients with UCB there was an expected distribution of histological grades and stages, and a mean age of 72 years (range 29 to 94 years, n=466); for the non-UCB (control) subjects the mean age was 71 years (range 34 to 88 years, n=52).
Full length EN2 protein could be detected in the urine of cancer patients by western blotting (Fig 4a) ; to quantify the EN2 concentration in all of the samples, the urine was also analyzed by ELISA. The mean urinary EN2 concentration in patients with UCB was 197ng/ml, whilst that for control subjects was 34ng/ml (Fig 4b) . The majority of UCB patients were diagnosed with stage Ta or T1 tumors, and there was no significant difference between the mean urinary EN2 concentrations in these patients (171ng/ml and 184ng/ml, respectively). The concentration of EN2 in the urine of patients with T2+ tumors was significantly higher than in those with Ta and T1 tumors, at 261ng/ml. Higher grade tumors (Grades 2 and 3) were associated with higher mean urinary EN2 concentrations (192ng/ml for Grade 2 and 215ng/ml for Grade 3) than Grade 1 tumors (168ng/ml).
Urinary EN2 concentrations are predictive for UCB
The difference in urinary EN2 concentrations in patients with and without UCB indicated potential diagnostic value. A ROC analysis of these data gave an area under the curve of 0.844, which rises to 0.908 when comparing cancer patients to those individuals with entirely normal histology (Fig 4c) . The ROC analysis indicated that the optimal urinary EN2 concentration threshold for cancer versus non-cancer was 55.5ng/ml in order to maximize the sensitivity and specificity of the test. Using this cut-off gives a sensitivity for all UCB of 82% with a specificity of 75%. The sensitivity for stages Ta, T1 and T2+ are 71%, 76% and 94%, respectively (Table 1) . Amongst the non-UCB patients, 19% had >55.5ng/ml EN2 in their urine (4% for patients with entirely normal histology).
.
Discussion
In this study we have shown that EN2 is expressed by and secreted from UCB tumors. These results highlight a potential role for EN2 in UCB pathogenesis (as seen in breast and prostate cancer 5, 6 ), and they also highlight the potential utility of EN2 as a urinary biomarker for UCB.
Specifically, EN2 appears to be a more sensitive marker for NMIBC than existing markers. As EN2 expression was also detected in non-transitional cell tumors (squamous cell and adenocarcinoma), it will be important to establish whether EN2 is also secreted into urine by patients harboring these forms of bladder cancer. A variety of molecular changes are associated with squamous cell and adenocarcinoma histology and, combined with evidence of EN2 expression/secretion in NMIBC and MIBC, it suggests a common regulatory defect. This is currently being investigated by our group. Squamous cell histology is common in countries where bladder cancer is associated with schistosomiasis 13 and therefore EN2 may be useful in this high risk population, in contrast with other currently used markers which have been shown to be more specific for TCC histology.
Current urinary biomarkers for UCB have important, significant limitations and none are reliable for post-treatment surveillance. In the evaluation of urinary EN2 as a diagnostic biomarker for UCB, EN2 was detected in the urine of most patients with NMIBC with an overall sensitivity of 82% and specificity of 75%. In comparison, urine cytology has a high diagnostic specificity (78-100%), but lacks robust sensitivity (12.2-84.6%), especially for low and intermediate grade tumors 14 . The sensitivity of EN2 for stage Ta and T1 tumors was 71% and 76%, respectively, and 94% for stage T2+ tumors. This compares favorably with existing markers. The sensitivity for tumor grades 1, 2, and 3 was 69%, 78% and 87% respectively. This latter result apparently contradicts our IHC findings where EN2 staining was found to be relatively weaker in higher grade tumors. The most likely explanation for this would be that the structure of high grade tumors, and / or some aspect of their physiology allows for a more efficient release of EN2 protein into the urine.
A number of other investigational urine markers have been described by Tilki et al in their recent review 15, 16 , but currently the presence of Nuclear Matrix Protein 22 (NMP22) protein in urine represents the most sensitive proteinbased non-invasive test for early stage UCB . NMP22, a regulator of mitosis that escapes from bladder cancer cells undergoing apoptosis, can be detected in the urine and has been studied as a potential biomarker 15 . It has a sensitivity of 46.7% and 48.2% for stages Ta and T1, respectively (a superior sensitivity to urine cytology), and a specificity of 90.3% in the absence of any urinary tract disease (reduced to 77.6% in inflammatory conditions) 17 . The fact that its sensitivity for stages Ta and T1 does not exceed 50% may reflect the primary mechanism for NMP22 release, thought to be the breakdown of cell membranes during apoptosis. Since earlier stage tumors undergo less apoptosis than more advanced tumors 18 , NMP22 release might also be expected to be less, limiting its diagnostic utility for NMIBC.
Conversely, EN2 is actively secreted from viable cells 19, 20 and its presence in urine is likely to be associated with live tumor cells. Like NMP22, a number of other diagnostic tools also have a relatively high sensitivity for more advanced stage cancers (stages T2+), but none of them currently allow for detection of more than 50% of earlier stage cancers. Upon validation, the first clinical application for urinary EN2 would be as a diagnostic test for patients either presenting for the first time (at a haematuria clinic), in order to increase diagnostic sensitivity and specificity, or for those under surveillance with an aim to reducing the number of screening cystoscopies. For both of these scenarios, the majority of patients will have NMIBC. EN2 may also be used as one of a panel of urinary markers, to provide a combined risk assessment 21, 22 .
We have found that EN2 is expressed in NMIBC and MIBC, and also in In previous studies, we demonstrated the potential utility of urinary EN2 for the diagnosis of prostate cancer 6, 7 which raises the question of how to interpret elevated urinary EN2 levels. This may be addressed in a number of ways. Firstly, the mean urinary concentration of EN2 in prostate cancer was 329ng/ml compared to 197ng/ml for UCB in this study, although the optimal cut-off values were similar (42.5ng/ml for prostate cancer and 55.5ng/ml for 'G1' -Grade G1, 'G2' -Grade G2, 'G3' -Grade 3, 'Non Ca' -all non-cancer
